ATAI Life Sciences BV Cash Flow Conversion Efficiency
ATAI Life Sciences BV cash flow conversion efficiency. Based on the latest financial reports, ATAI Life Sciences BV (ATAI) has a cash flow conversion efficiency ratio of -0.106x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-21.09 Million) by net assets ($198.78 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of ATAI Life Sciences BV (2019–2025)
Cash flow conversion efficiency of ATAI Life Sciences BV from 2019 to 2025. This chart illustrates how ATAI Life Sciences BV's cash flow conversion efficiency has evolved over time, based on yearly financial data. View today's stock price for ATAI Life Sciences BV for real-time trading data and today's change.
ATAI Life Sciences BV Cash Flow Conversion Ratio Explained
ATAI Life Sciences BV cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
ATAI Life Sciences BV Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of ATAI Life Sciences BV ranked by their cash flow conversion efficiency. Also see ATAI market cap for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
President Securities Corp
TW:2855
|
-0.017x |
|
FRASERS PROPERTY
F:1IQ
|
N/A |
|
Disc Medicine Inc.
NASDAQ:IRON
|
-0.069x |
|
Gold Road Resources Ltd
AU:GOR
|
0.122x |
|
Shikun & Binui
TA:SKBN
|
-0.001x |
|
AVIC Heavy Machinery Co Ltd
SHG:600765
|
-0.015x |
|
PT Petrindo Jaya Kreasi Tbk
JK:CUAN
|
0.099x |
|
Foxconn Technology Co Ltd
TW:2354
|
0.045x |
Annual Cash Flow Conversion Efficiency for ATAI Life Sciences BV (2019–2025)
The table below shows the annual cash flow conversion efficiency of ATAI Life Sciences BV from 2019 to 2025. Review ATAI Life Sciences BV free cash flow efficiency to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $222.00 Million | $-102.67 Million | -0.462x | +34.61% |
| 2024-12-31 | $116.55 Million | $-82.44 Million | -0.707x | -105.43% |
| 2023-12-31 | $244.32 Million | $-84.12 Million | -0.344x | +12.41% |
| 2022-12-31 | $265.77 Million | $-104.47 Million | -0.393x | -139.88% |
| 2021-12-31 | $385.96 Million | $-63.25 Million | -0.164x | +24.74% |
| 2020-12-31 | $95.37 Million | $-20.77 Million | -0.218x | -65.90% |
| 2019-12-31 | $59.78 Million | $-7.85 Million | -0.131x | -- |
About ATAI Life Sciences BV
AtaiBeckley Inc., a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of mental health treatments in the United States, Germany, and Canada. The company develops BPL-003, an intranasal formulation of the benzoate salt form of mebufotenin that is in Phase 2a and 2b clinical studies for treatment resistant depression (TRD) and alcohol use disorder… Read more